20 Jun 2014 10:59
20 June 2014 - PuriCore plc (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, today announces that the resolution to approve the sale of PuriCore International Limited was duly passed at its General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's investor website at http://investor.puricore.com.
Accordingly, the sale of PuriCore International Limited, announced on 4 June 2014, is expected to complete on 30 June 2014, pending consent being received from the NHS in England and Scotland to the change of control of PuriCore International Limited.
The resolution will be available shortly for inspection at the National Storage Mechanism at www.hemscott.com/nsm.do.
Enquiries: | |
UK | US |
FTI Consulting | Sage Strategic Marketing |
Mo Noonan/Simon Conway | Jennifer Guinan |
Victoria Foster Mitchell | +1 610.410.8111 |
+44 203 727 1000 | jennifer@sagestrat.com |
About PuriCore
PuriCore plc (LSE: PURI) is a global company focused on safe and effective protection against the spread of infectious pathogens without causing harm to human or animal health or to the environment. PuriCore's antimicrobial technology and complementary products are used in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients and staff in UK hospitals. PuriCore's breakthrough wound care technology is used to treat chronic and acute wounds including diabetic ulcers and burns in humans, for atopic dermatitis as private-labelled dermatologic treatments for humans, and to manage wounds in all species of companion and farm animals in the animal health segment. In the Food & Agriculture market, PuriCore's portfolio is used by three of the top-five US supermarket retailers to provide savings in labour costs and improvements in inventory loss and to address cross contamination of pathogens on fresh produce and floral products. In addition, the Company is progressing its research and development programmes on the use of its technology as an agricultural fungicide. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com.